No new or changed patents today — the tracked watch list is unchanged since the last update.
All Tracked Patents (6)
PENDING Subject technology
Institute of Molecular and Clinical Ophthalmology Basel (IOB) · Temurkhan Ayupov, Veronica Moreno-Juan, Simon Hansen, Botond Roska
The subject technology. Novelty likely rests on the specific binder combination (TOMM20 x endogenous receptor) rather than the bispecific format itself. Composition-of-matter claims would be strong; method-of-use claims are more designable-around. No WO number public yet.
PCT (pending, no WO number public) · Priority: unknown
GRANTED High FTO concern
Mor Research Applications Ltd
GRANTED (not merely pending) and covers the exact ocular indications where MitoCatch's strongest efficacy data lives (LHON/optic atrophy, RGC survival - the C-variant 46.8% / 23.6% numbers). Strongest freedom-to-operate concern for MitoCatch's ophthalmology indication. MitoCatch's differentiator is active bispecific targeting vs. this patent's passive uptake, but the delivery-route and disease-indication overlap warrants an FTO review.
US12478644B2 (application US20220168358A1) · Priority: 2019-04-03 · Granted: 2025-11-25
PUBLISHED Medium / watch
Yale University / University of Rhode Island
Conceptually adjacent to the MitoCatch-C variant's cell-surface display approach. Freedom-to-operate review candidate for the C variant (the least clinically translatable variant, but the one with the disease-rescue data).
US20200246420A1 · Priority: unknown
PUBLISHED Medium / watch
Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences
Emerging competitor delivery platform (Parkinson's, mtDNA depletion syndrome, Leigh syndrome), published in Cell March 2026. Different mechanism (vesicle encapsulation vs. bispecific binder) but same commercial space. No matching patent found yet in English-language search; a Chinese-priority filing likely exists but has not surfaced. Watch item, not yet assessed for claims overlap.
no patent number surfaced yet (likely Chinese-priority filing) · Priority: unknown
PUBLISHED Low concern
Boston Children's Hospital (McCully) · James D. McCully
Foundational autologous mito-transplant prior art. Not cell-type targeted, so conceptually distinct from MitoCatch, but establishes broad mito-transplant delivery-vehicle claims worth being aware of.
US20180057610A1 · Priority: unknown
PUBLISHED Low concern
(various - general bispecific nanobody format)
The bispecific nanobody FORMAT itself is prior art, so MitoCatch's Bi variant cannot claim novelty on format alone - novelty must rest on the specific target pairing. Confirmed EP3049439A1 is the format patent (previously cited only as US20160251440A1).
EP3049439A1 (family incl. US20160251440A1) · Priority: unknown